Clinical Center of Vojvodina patients start received new drug against Covid

Patients at the Clinical Center of Vojvodina (KCV) have started receiving a new drug against Covid-19, Bamlanivimab, which prevents further spread of the infection, that is, the progression of the disease from mild to severe, KCV Director Edita Stokic has told Tanjug.

Recommended

In this way, the number of hospitalizations due to complications caused by the Covid viral infection is reduced and the development of a severe form of the disease is prevented.

This therapy can be received by patients older than 65 or those older than 55 who have comorbidities like cardiovascular diseases, arterial hypertension or chronic obstructive pulmonary disease, said Stokic.

She added that this medicine is given to patients when a doctor's council makes that decision, while the course and the duration of therapy lasts about an hour, after which the patients return to home isolation.

The patients who have received this therapy say that they trust the medicine and expect the best. The drug is given once, in the form of an infusion, after which the patient returns to home treatment.

(Telegraf.rs/Tanjug)